In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Phio Pharmaceuticals Corp.

www.phiopharma.com

Latest From Phio Pharmaceuticals Corp.

Tech Transfer Roundup: Tonix Obtains Triple-Reuptake Inhibitor For PTSD From Wayne State

TNX-1600 joins two other candidates, including Phase III TNX-102 SL, in Tonix’s PTSD portfolio. CureVac and Yale partner on mRNA therapies for pulmonary disease.

Commercial Deals

Phio Pharma Takes RXi’s Self-Delivering RNAi Technology, Refocuses On Immuno-Oncology

RXi thought it had solved the RNAi delivery issue but was focused on dermatology and ophthalmology. New CEO Dispersyn thought the platform offered more lucrative promise as a way of optimizing IO therapy.

Business Strategies Platform Technologies

Tech Transfer Roundup: Mustang Licenses St. Jude’s Gene Therapy For Bubble Boy Disease

Fortress Biotech’s subsidiary will add the lentiviral gene therapy now in pair of Phase I/II trials to its pipeline. RXi partners with Karolinska to advance its self-delivering RNAi technology, while Avalon enlists Weill Cornell to enhance its CAR-T capabilities.

Deals Intellectual Property

Pipeline Watch: Phase III Starts With Bavencio, MultiStem And VT-1161

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

 

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Drug Discovery Tools
      • Molecular Diversity
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Dermatology
  • Ophthalmic
  • Alias(es)
  • RXi Pharmaceuticals Corp.
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Phio Pharmaceuticals Corp.
  • Senior Management
  • Gerrit Dispersyn, PhD, Pres. & CEO
    John A Barrett, Chief Dev. Officer
    James Cardia, PhD, VP, Bus. Operations
    Caitlin Kontulis, VP, Fin. & Admin.
  • Contact Info
  • Phio Pharmaceuticals Corp.
    Phone: (508) 767-3861
    257 Simarano Dr.
    Ste. 101
    Marlborough, MA 01752
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register